Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

SUMMARY: The challenge of harnessing tolerance as a therapeutic modality has been greatly influenced by dogmas dictating how self-tolerance comes about. Deletional strategies popularized from the classical work of Medawar and Owen have always demanded stringent attention to eliminating all antigen-reactive cells. This was always considered a tough call for the treatment of autoimmune disease, where the number of antigens and their identity were hard to predict. The finding, some 15 years ago, that therapeutic tolerance could be elicited with non-lytic CD4 monoclonal antibodies using regulatory T cells as major operatives has opened up a new dimension in exploiting tolerance mechanisms for drug minimization in transplantation and for providing short-term treatments for long-term benefit in allergy, autoimmunity, transplantation, and other immunopathological conditions. Resolution of the mechanisms underlying tolerance induced by CD4 co-receptor blockade have provided a general paradigm for how regulatory T cells might be directed to get the upper hand in preventing disease. They have also identified an unexpected role for tissues to contribute to their own protection.

Original publication

DOI

10.1111/j.1600-065X.2008.00632.x

Type

Journal article

Journal

Immunol Rev

Publication Date

06/2008

Volume

223

Pages

361 - 370

Keywords

Animals, Antibodies, Blocking, Antigens, CD4, Autoimmune Diseases, CD4-Positive T-Lymphocytes, Humans, Immune Tolerance, Immunotherapy, Mice, Organ Transplantation, T-Lymphocytes, Regulatory, Transforming Growth Factor beta, Transplantation Immunology